CURE

Onvansertib Combo Improves Outcomes in First-Line RAS-Mutated mCRC

Onvansertib combined with FOLFIRI and Avastin shows dose-dependent improvements in tumor response and disease control for RAS ...

Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in ...
ascopubs.org

Phase II study of FOLFIRI with low-dose irinotecan plus ramucirumab as second-line treatment in Japanese patients with metastatic colorectal cancer (RINDO study).

First-in-human, phase 1a, dose escalation study of BGB-B167, a CEA x 4-1BB bispecific antibody, as monotherapy or combined with tislelizumab (anti-PD-1), in patients with selected advanced or ...
CURE

Key GI Cancer Advances from the 2026 ASCO Symposium

This years 2026 ASCO Gastrointestinal Cancers Symposium was packed with practice-shaping data across colorectal and upper ...

Cardiff Oncology, Inc.: Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC

Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patie ...